TY  - JOUR 
AU  - Romo González, Marta
AU  - Moreno-Paz, Sara
AU  - García Hernández, Violeta
AU  - Sánchez Guijo Martín, Fermín
AU  - Hernández Hernández, Ángel
PY  - 2020
UR  - http://hdl.handle.net/10366/155176
AB  - [EN]Chronic myeloid leukemia (CML) is characterized by the expression of the oncogenic
kinase BCR-ABL. Although tyrosine kinase inhibitors (TKIs) against BCR-ABL represent the standard
therapeutic option for CML, resistances to TKIs can be a serious...
LA  - eng
PB  - MDPI
KW  - Chronic myeloid leukemia (CML)
KW  - Reactive oxygen species (ROS)
KW  - BCR-ABL
KW  - Xanthine oxidoreductase (XOR)
KW  - Allopurinol
KW  - Tyrosine kinase inhibitors (TKIs)
KW  - Imatinib
KW  - Nilotinib
KW  - Leukemia
KW  - Allopurinol
TI  - Inhibition of xanthine oxidoreductase enhances the potential of tyrosine kinase inhibitors against chronic myeloid leukemia
DO  - 10.3390/ANTIOX9010074
T2  - Antioxidants
VL  - 9
M2  - 74
ER  -